{
    "id": "34a4933a-9b54-1f14-e063-6394a90a7b59",
    "indications": "eszopiclone tablets indicated treatment insomnia . controlled outpatient sleep laboratory , eszopiclone tablets administered bedtime decreased sleep latency improved sleep maintenance . trials performed support efficacy 6 months duration . final formal assessments sleep latency maintenance performed 4 weeks 6-week study ( adults ) , end 2-week ( elderly ) end 6-month study ( adults ) .",
    "contraindications": "lowest effective dose patient .",
    "warningsAndPrecautions": "eszopiclone tablets usp 2 mg white off-white , film-coated , round shaped , biconvex tablets debossed ‘ k ’ one side ‘ 84 ’ side . ndc : 70518-1310-00 packaging : 30 1 bottle plastic store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "eszopiclone tablets contraindicated patients experienced complex sleep behaviors taking eszopiclone tablets [ ( 5.1 ) ] . eszopiclone tablets contraindicated patients known hypersensitivity eszopiclone . hypersensitivity include anaphylaxis angioedema [ ( 5.3 ) ] .",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "ESZOPICLONE",
            "code": "UZX80K71OE"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "ESZOPICLONE",
    "effectiveTime": "20250508",
    "indications_original": "Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. \n                  \n                  The clinical trials performed in support of efficacy were up to 6 months in duration.  The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).",
    "contraindications_original": "Use the lowest effective dose for the patient.",
    "warningsAndPrecautions_original": "Eszopiclone Tablets USP 2 mg are white to off-white, film-coated, round shaped, biconvex tablets with debossed ‘K’ on one side and ‘84’ on other side.\n                  NDC: 70518-1310-00\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Eszopiclone tablets are contraindicated in patients who have experienced complex sleep behaviors after taking Eszopiclone tablets \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.1)]. \n        \n  \n   \n                     \n                  \n                  \n                     Eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.3)]\n        \n  \n   ."
}